FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2023-06, Vol.37 (6), p.1379-1383
Hauptverfasser:	Jia, Yannan, Zhang, Weiguo, Basyal, Mahesh, Chang, Kyung Hee, Ostermann, Lauren, Burks, Jared K., Ly, Charlie, Mu-Mosley, Hong, Zhang, Qi, Han, Xin, Fogler, William E., Magnani, John L., Lesegretain, Arnaud, Zal, Anna A., Zal, Tomasz, Andreeff, Michael
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67/1059/2326 692/308/575 96 96/100 96/106 96/2 96/21 96/31 96/35 96/44 96/63 96/95 Acute myeloid leukemia Cancer Research Cancer therapies Cell adhesion & migration Chemokines Critical Care Medicine CXCR4 protein Cytokines Drug dosages E-Selectin fms-Like Tyrosine Kinase 3 Hematology Humans Hypotheses Hypoxia Intensive Internal Medicine Letter Leukemia Leukemia, Myeloid, Acute - drug therapy Ligands MAP Kinase Signaling System Medical prognosis Medicine Medicine & Public Health Mutation Oncology Patients Protein Kinase Inhibitors - pharmacology Receptors, CXCR4 - genetics Signal Transduction
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!